Sichuan Kelun Pharmaceutical Co., Ltd.

SZSE:002422 Stock Report

Market Cap: CN¥49.2b

Sichuan Kelun Pharmaceutical Future Growth

Future criteria checks 1/6

Sichuan Kelun Pharmaceutical is forecast to grow earnings and revenue by 10.6% and 9.2% per annum respectively. EPS is expected to grow by 10.3% per annum. Return on equity is forecast to be 14.2% in 3 years.

Key information

10.6%

Earnings growth rate

10.3%

EPS growth rate

Pharmaceuticals earnings growth19.3%
Revenue growth rate9.2%
Future return on equity14.2%
Analyst coverage

Good

Last updated30 Aug 2024

Recent future growth updates

Recent updates

Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Aug 16
Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Jul 12
Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

Jun 11
Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

May 21
An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

May 02
Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Mar 19
If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Mar 04
Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Feb 27
These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Earnings and Revenue Growth Forecasts

SZSE:002422 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202628,3533,737-1,0225,0037
12/31/202525,2743,299-1,9634,3308
12/31/202423,4503,057-1,8384,4753
6/30/202422,5112,8502,4584,461N/A
3/31/202422,0352,6683,1285,109N/A
12/31/202321,4542,4563,5685,337N/A
9/30/202320,8772,2674,1685,433N/A
6/30/202320,6842,2444,2695,257N/A
3/31/202320,1942,2283,6934,591N/A
1/1/202319,0381,7052,2303,127N/A
9/30/202218,5311,6601,8162,726N/A
6/30/202218,1701,4782,1853,208N/A
3/31/202217,6081,2181,9892,982N/A
1/1/202217,2771,1031,8572,847N/A
9/30/202117,4871,1761,9153,034N/A
6/30/202117,4651,1191,0982,247N/A
3/31/202117,0789831,0322,277N/A
12/31/202016,4648299882,219N/A
9/30/202016,342525801,361N/A
6/30/202015,9454122971,608N/A
3/31/202016,8866242341,524N/A
12/31/201917,6369388862,217N/A
9/30/201917,0781,1041,5733,156N/A
6/30/201917,4821,1672,0653,344N/A
3/31/201916,7081,1651,4302,757N/A
12/31/201816,3521,2131,6242,954N/A
9/30/201815,7571,3841,2232,258N/A
6/30/201814,2851,2651521,608N/A
3/31/201812,933938N/A1,736N/A
12/31/201711,435748N/A1,203N/A
9/30/201710,223434N/A1,081N/A
6/30/20179,412455N/A1,493N/A
3/31/20178,996569N/A1,398N/A
12/31/20168,566585N/A1,725N/A
9/30/20168,198632N/A1,590N/A
6/30/20168,024622N/A1,525N/A
3/31/20167,875648N/A1,712N/A
12/31/20157,763645N/A1,239N/A
9/30/20157,856727N/A1,345N/A
6/30/20157,892874N/A1,237N/A
3/31/20157,976980N/A1,205N/A
12/31/20148,0231,002N/A1,219N/A
9/30/20147,8881,057N/A1,242N/A
6/30/20147,6171,082N/A1,226N/A
3/31/20147,3101,101N/A1,080N/A
12/31/20136,8311,080N/A1,050N/A
9/30/20136,4611,170N/A915N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002422's forecast earnings growth (10.6% per year) is above the savings rate (2.9%).

Earnings vs Market: 002422's earnings (10.6% per year) are forecast to grow slower than the CN market (23.1% per year).

High Growth Earnings: 002422's earnings are forecast to grow, but not significantly.

Revenue vs Market: 002422's revenue (9.2% per year) is forecast to grow slower than the CN market (13.4% per year).

High Growth Revenue: 002422's revenue (9.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002422's Return on Equity is forecast to be low in 3 years time (14.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y